Healthcare / Pharmaceutical RetailersKuala Lumpur
$0.61
+0.00 (+0.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $12.1M · quality 77.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$184M
P/E
20.5x
↑EV/EBITDA
9.3x
↓ROE
2.7%
↑Gross Margin
40.5%
↓Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-9.5%
FCF CAGR
-21.0%
FCF margin
7.8%
FCF / Net income
1.42x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $155.1M · net income $8.5M · FCF $12.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $155.1M | $155.1M | $151.1M | $174.2M | $209.6M |
| Net Income | $8.5M | $8.5M | $10.9M | $16.3M | $28.2M |
| EBITDA | $18.1M | $18.1M | $20.2M | $30.0M | $46.6M |
| EPS | — | — | 0.04 | 0.05 | 0.09 |
| Gross Margin | 40.5% | 40.5% | 41.5% | 42.0% | 41.1% |
| Operating Margin | 8.1% | 8.1% | 9.3% | 13.8% | 19.4% |
| Net Margin | 5.5% | 5.5% | 7.2% | 9.3% | 13.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.01 | 0.01 | 0.01 |
| Current Ratio | 6.55 | 6.55 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $12.1M | $12.1M | $17.9M | $7.7M | $24.5M |
| Returns | |||||
| ROE | 2.7% | 2.7% | 3.5% | 5.3% | 8.9% |
| Valuation | |||||
| P/E | 20.50 | 20.50 | 25.21 | 21.92 | 16.91 |
| EV/EBITDA | 9.33 | 9.33 | 12.08 | 10.86 | 9.09 |
| P/B | 0.60 | 0.60 | 0.89 | 1.15 | 1.50 |
| Growth & Yield | |||||
| Revenue Growth | 2.6% | 2.6% | -13.3% | -16.9% | — |
| EPS Growth | — | — | -33.1% | -42.6% | — |
| Dividend Yield | 3.3% | 3.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.1%
Start / end P/E
n/dx → n/dx
EPS bridge
0.04 → n/d
Residual
-3.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.